Goldman Sachs analyst David Roman initiated coverage of Doximity (DOCS) with a Neutral rating and $58 price target The firm has a constructive view on the fundamentals of the business but does not see further room for multiple expansion with the shares up 68% year-to-date. As such, Doximity’s current valuation creates a balanced risk/reward, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- American upgraded, Regeneron initiated: Wall Street’s top analyst calls
- Doximity price target raised to $49 from $35 at Truist
- Doximity upgraded to Equal Weight from Underweight at Morgan Stanley
- Starbucks, Spotify downgraded: Wall Street’s top analyst calls
- Doximity downgraded to Hold from Buy at Canaccord